White Bear Lake, Minnesota — November 4, 2025 — Leads & Copy — Envoy Medical, Inc. (NASDAQ: COCH) announced the enrollment of the first three patients in the final stage of its pivotal clinical trial for the fully implanted Acclaim® cochlear implant. The surgeries were performed by Dr. Abraham Jacob in Tucson, Arizona, and Dr. Jack Shohet in Seal Beach, California.
The Acclaim® device operates without external wearable components, using a novel sensor to capture sound by leveraging the ear’s natural anatomy, eliminating the need for an external microphone or sound processor.
Dr. Jack Shohet noted strong interest from patients eager to participate in the study. Dr. Abraham Jacob highlighted patient inquiries from various locations expressing interest in the fully implanted device.
Envoy Medical CEO Brent Lucas stated the enrollment brings the company closer to FDA submission and commercialization. A total of 46 patients will be implanted in the final stage of the trial, with 43 spots remaining.
The Acclaim cochlear implant received Breakthrough Device Designation from the FDA in 2019. Visit www.envoymedical.com/acclaim-pivotal for trial information.
Investor Contact: Phil Carlson, KCSA Strategic Communications, O: 212.896.1233, E: Envoy@kcsa.com
Media Contact: Anne Donohoe, KCSA Strategic Communications, O: 732-620-0033, E: Envoy@kcsa.com
Source: Envoy Medical
